Drug Trial Radar · NCT06678399
Phase 1B/2 Clinical Trial Assessing the Safety, Tolerability and Preliminary Efficacy of the Intravenous Administration of Allogeneic Placental Mesenchymal Cells for the Preemptive Treatment of Patients At Risk for Acute Kidney Injury Following Cardiac Surgery
Last checked: Nov 19, 2026Latest source record: Nov 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
91
Planned (sponsor's estimate)
Start
Apr 1, 2025
Primary completion
Oct 1, 2026
Study completion Jan 1, 2027
Sponsor
- Lead sponsor
- KelifarmaIndustry
- Sponsor type
- Industry
- First posted
- Nov 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial is designed to evaluate KELI-101 versus placebo for the prevention of acute kidney disease leading to chronic kidney disease in subjects at high risk for acute kidney injury following cardiac surgery. Half of the participants will receive KELI-101, while the other half will receive a placebo.
Conditions
- Preemptive Therapy of Patients At Risk for Acute Kidney Injury Following Cardiac Surgery
Interventions
KELI-101Drug
KELI-101 consists of ex vivo expanded placental mesenchymal stromal cells (PMSCs) in a 10% cryopreservation solution.
Vehicle (placebo)Other
Plasmalyte
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment-emergent adverse events (TEAE)Time frame: From KELI -101 administration up to Day 90
- Ratio of the acute kidney disease (AKD) leading to chronic kidney disease (CKD)Time frame: From baseline to Day 90
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.